drug
Facioscapulohumeral Muscular Dystrophy (FSHD)
Preclinicalupdated 6mo agoby Altay Therapeutics Inc
Preclinicalcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
News(10)
- Sarepta’s new CEO confident in clinical execution as DMD competitors close inSarepta Therapeutics’ newly minted CEO Michael Severino laid out his path to returning the muscular dystrophy therapy maker to the forefront of the rapidly expanding market.biospace · 10d ago
- On the move: 4 rare disease companies hiring nowBiotechs developing therapeutics to treat rare diseases include two that received FDA approvals this year for drugs to treat spinal muscular atrophy and Alexander disease.biospace · 1mo ago
- Epicrispr builds case for FSHD treatment with updated data for EPI-321Epicrispr Biotechnologies continued to show encouraging findings from testing of its epigenetic editing treatment for the genetic muscle disease facioscapulohumeral muscular dystrophy. Twelve peopl…endpoints · 1mo ago
- Roche drops muscle-sparing obesity antibody after flunked interim analysisRoche has slammed the brakes on an obesity antibody after the candidate showed little hope of hitting its endpoints in a phase 2 study.fiercebiotech · 1mo ago
- After Novartis’ devastating M&A losses, long live the executive willing to tryBig Pharma needs more—not fewer—bold bets on rare and difficult diseases after Novartis’ efforts to invest in muscular dystrophy and ALS hit major roadblocks this month.biospace · 2mo ago
- Novartis stock slides as centerpiece of $12B Avidity buyout flunks ‘crucial’ phase 3 testThe phase 3 Harbor trial of Novartis’ del-desiran has missed its primary endpoint, dealing a major blow to an asset that the Swiss drugmaker acquired in the $12 billion takeover of Avidity Bioscien…fiercebiotech · 2mo ago
- Epicrispr, Infinimmune snag combined $165M in VC cashEpicrispr Biotechnologies is working on an epigenetic medicine for facioscapulohumeral muscular dystrophy, while Infinimmune will advance a pair of antibodies for atopic dermatitis.biospace · 3mo ago
- Epicrispr lands $90M to advance epigenetic editing drug for rare muscle diseaseThe startup has completed enrollment of an early-stage study testing a first-of-its-kind treatment for facioscapulohumeral muscular dystrophy, a disease targeted by many other drugmakers.biopharma_dive · 3mo ago
- Epicrispr raises $90M to rewrite treatment of rare muscle diseaseEpicrispr Biotechnologies has raised $90 million in a series C round backed by investors including Sanofi Ventures, positioning the biotech to advance a pipeline of epigenetic medicines led by an e…fiercebiotech · 3mo ago
- 4 potential biotech M&A targets, plus a pretty sure bet from J&JPharma is definitely interested in making more deals. But what biotechs will come under the magnifying glass? BioSpace takes a look at companies that analysts see as near-term targets for buyouts.biospace · 3mo ago
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that